Dynamics of arachidonic acid mobilization by inflammatory cells by Astudillo, Alma M. et al.
Biochim Biophys. Acta (2012) 1821: 249‐256 
Dynamics of Arachidonic Acid Mobilization by 
Inflammatory Cells 
 
Alma M. Astudillo, David Balgoma, María A. Balboa, and Jesús Balsinde* 
 
Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones 
Científicas (CSIC), 47003 Valladolid, Spain, and 
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas 
Asociadas (CIBERDEM), 08036 Barcelona, Spain 
 
 
 
*Corresponding author. Phone, +34-983-423-062; Fax, +34-983-184-800;  
e-mail: jbalsinde@ibgm.uva.es 
 
 
Keywords: Arachidonic Acid; Phospholipid Remodeling; Eicosanoid Metabolism; 
Lipidomics; Mass Spectrometry.  
 
 
Running Title:  AA Mobilization in Inflammatory Cells 
 
 1
Biochim Biophys. Acta (2012) 1821: 249‐256 
Abstract  
The development of mass spectrometry-based techniques is opening new insights into the 
understanding of arachidonic acid (AA) metabolism. AA incorporation, remodeling and 
release are collectively controlled by acyltransferases, phospholipases and transacylases 
that exquisitely regulate the distribution of AA between the different glycerophospholipid 
species and its mobilization during cellular stimulation. Traditionally, studies involving 
phospholipid AA metabolism were conducted by using radioactive precursors and 
scintillation counting from thin layer chromatography separations, that provided only 
information about lipid classes. Today, the input of lipidomic approaches offers the 
possibility of characterizing and quantifying specific molecular species with great 
accuracy and within a biological context associated to protein and/or gene expression in a 
temporal frame. This review summarizes recent results applying mass spectrometry-
based lipidomics approaches to the identification of AA-containing 
glycerophospholipids, phospholipid AA remodeling and synthesis of oxygenated 
metabolites. 
 
Abbreviations: AA, arachidonic acid; PLA2, phospholipase A2; cPLA2α, group IVA 
cytosolic PLA2; iPLA2, Ca2+-independent PLA2; sPLA2, secreted PLA2; CoA-IT, CoA-
independent transacylase; ACS, acyl-CoA synthetase; ESI, electrospray ionization; 
HPLC, high performance liquid chromatography; MS, mass spectrometry; TLC, thin 
layer chromatography; PC, choline glycerophospholipids; PE, ethanolamine 
glycerophospholipids; PI, phosphatidylinositol. 
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1. Introduction  
The traditional view of lipids typically acting as membrane building blocks or  
fuel has changed dramatically in recent years. Now, it is widely accepted that these 
biomolecules are centrally involved in cell signaling, and that imbalances in lipid 
metabolism are causative agents of a number of high-prevalence disorders, ranging from 
cardiovascular disease, diabetes and obesity to cancer [1-3]. Hundreds to thousands of 
lipid species can be identified in a given biological system at a cell or tissue levels, each 
of them with a particular distribution and function [4]. 
 The significant advances in analytical techniques over the last years, especially 
mass spectrometry (MS) and the parallel improvement in molecular ionization, together 
with the possibility to use this technique as a detector in chromatographic separation, 
have constituted a breakthrough in lipid analysis and, therefore, a better understanding of 
lipid biochemistry has been possible. This has contributed to the development of 
lipidomics [5-7], a branch of metabolomics that pursues a thorough scientific study of 
lipids. Lipidomics not only aims at characterizing and analyzing lipid species in a 
particular state of the cell —called the static composition—, but also aims at integrating 
the understanding of lipid pathways (synthesis, remodeling or transport) with their 
biological roles and with gene regulation and protein expression [5, 7-11].  
 There are two major strategies for lipidomic analysis. The first one, called global 
lipidomics, pursues the analysis of the whole lipidome of biological samples, by using 
either direct infusion methods or previous liquid chromatography steps. On the other 
hand, targeted or focused lipidomics, is based on setting conditions for analysis of 
specific categories of lipids, thus improving sensitivity  [11-14]. 
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 As lipidomics is focused on profiling the static composition of molecular species 
in biological samples, the term metabolipidomics has been coined to emphasize the 
dynamical aspects of lipids in cells, organs, tissues and whole organisms [15]. In this 
case, lipids containing stable isotopes are used to follow their metabolic fate through the 
various possible pathways, thus facilitating the identification of minor species with rapid 
turnover rates. 
 
 
2. Cellular Utilization of Arachidonic Acid  
 Arachidonic acid (5,8,11,14-eicosatetraenoic acid) is an ω-6 essential fatty acid, 
obtained directly from diet or, alternatively, synthesized from linoleic acid (18:2n-6) 
through the successive actions of Δ6-desaturase, elongase and Δ5-desaturase, that occurs 
mainly in liver but also in other tissues (Figure 1). In western diets it is calculated that the 
intake of AA is 0.2-0.3 g/day, whereas the intake of linoleic acid is 10-20 g/day, 
indicating that the amount of AA coming from linoleic acid is higher than that coming 
directly from the diet [16, 17].  
 AA is the common precursor of the eicosanoids, a family of lipid mediators with 
key roles in physiology and pathophysiology, particularly in inflammatory reactions [18, 
19], although the fatty acid can exert potent biological roles by itself, e.g. by inducing 
apoptosis [20-22]. Additionally, when present in elevated concentrations, AA can give 
rise to significant quantities of its 2-carbon elongation product, adrenic acid (22:4n-6). 
Adrenic acid is the precursor of 22-carbon 1a,1b-dihomologue prostaglandins 
(dihomoprostaglandins) [23-26]. The potent biological activity of the eicosanoids 
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compels the cells to tightly control the leveles of free AA in such a manner that 
availability of free AA is frequently a rate-limiting step in eicosanoid generation [27, 28]. 
 In inflammatory cells, AA is generally found esterified in the sn-2 position of 
glycerophospholipids, particularly choline glycerophospholipids (PC), ethanolamine 
glycerophospholipids (PE), and phosphatidylinositol (PI) [28]. Cellular free AA levels 
are controlled by two competing reactions; on one hand, the phospholipase A2 (PLA2)-
mediated cleavage of the sn-2 position of phospholipids to yield the free fatty acid and, 
on the other, the CoA-dependent acyltransferase-modulated acylation reactions that re-
incorporate the free fatty acid into phospholipids [29, 30]. In resting unstimulated cells, 
the reacylation reactions dominate over the PLA2-mediated deacylation step; thus free 
AA is kept at very low levels. Stimulation of the cells by receptor agonists results in the 
activation of intracellular PLA2s [31-35]. Under these conditions, the rate of AA release 
clearly exceeds that of reincorporation into phospholipids; hence, net accumulation of 
free AA occurs that is followed by its conversion into various eicosanoids. Nevertheless, 
AA reacylation reactions are still very significant under stimulated conditions, as 
manifested by the fact that only a minor fraction of the free AA released by PLA2s is 
converted into eicosanoids, the remainder being effectively incorporated back into 
phospholipids [36, 37]. 
 The first step for AA incorporation into cellular lipids is the activation of the 
carboxyl group of the fatty acid by thioesterification with CoA. This reaction is catalyzed 
by acyl-CoA synthetases, of which there are many in cells [30]. In the context of AA 
metabolism it is worth mentioning the long chain acyl-CoA synthetases ACSL3, 4 and 6, 
as they show some selectivity towards AA [38-40]. The next step in the AA incorporation 
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is the esterification of the fatty acid into primarily the sn-2 position of 
glycerophospholipids, a reaction that is carried out by lysophospholipid:acyl CoA 
acyltransferases, in particular those of the membrane-bound O-acyltransferase family 
(MBOAT) [41]. Those that have been found to exhibit clear  preference for AA include 
lysoPC:acyl-CoA acyltransferase 2 [42], lysoPC:acyl-CoA acyltransferase 3 [43-45], 
LysoPI:acyl-CoA acyltransferase and lysophosphatidic acid:acyl-CoA acyltransferase 3 
[44, 46, 47]. In addition, the lipase CGI-58 shows lysophosphatidic:acyl-CoA 
acyltransferase with high preference towards AA [48]. For detailed information on the 
biochemistry and functioning of CoA-dependent acyl transferases, the reader is kindly 
referred to recent reviews on the subject [30, 49-51].  
 AA bound to phospholipid is also the subject of successive transacylation 
reactions aimed at ensuring the proper distribution of the fatty acid within the various 
cellular phospholipid pools [29, 30, 52-54]. This appears to be important not only for 
membrane homeostasis but also for the execution of appropriate cell responses during 
physiological and pathophysiological activation [55-59]. These transacylation reactions 
are catalyzed by CoA-independent transacylase (CoA-IT), an enzyme that transfers AA 
moieties preferentially from diacyl PC species to PE plasmalogens [29, 30] (Figure 1). 
The sequence of  CoA-IT is yet to be described. Thus, currently the only manner to study 
the cell regulation of CoA-IT is by following its enzyme activity [60, 61]. 
 Once the AA has been effectively incorporated into phospholipids the fatty acid 
can be eventually liberated, especially under cell stimulation conditions, by a number of 
PLA2 enzymes. So far, more than 30 enzymes possessing PLA2 activity have been 
described in mammals [62-64]. Attending to sequence homology criteria, the PLA2s have 
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been classified into 16 groups [62-65], although based on biochemical features they can 
be grouped into 5 main families, namely the Ca2+-dependent secreted PLA2s (sPLA2), 
Ca2+-dependent cytosolic PLA2s (cPLA2), Ca2+-independent cytosolic PLA2s (iPLA2), 
platelet-activating factor acetylhydrolases, and lysosomal PLA2s. Of these, the first two 
have been repeatedly implicated in receptor-mediated AA mobilization in response to a 
variety of stimuli. Today, it is firmly established that the calcium-dependent cytosolic 
group IVA PLA2α (cPLA2α) is the critical enzyme in stimulus-dependent AA 
mobilization and that, depending on cell type and stimulation conditions, a sPLA2 may 
also participate by amplifying the cPLA2α-regulated response [66-91]. Under some 
conditions, the Ca2+-independent group VIA iPLA2 may also effect the AA release [92-
94] but in other conditions, it mediates phospholipid reacylation reactions by regulating 
the steady-state level of lysoPC [95-97], reflecting the multiplicity of functions that this 
enzyme appears to serve depending on cell type [34, 98].  For detailed information on the 
cellular regulation of AA mobilization by PLA2 enzymes, the reader is kindly referred to 
the many comprehensive reviews that have been published in recent years covering 
different aspects of the subject [31-35, 51, 62-65, 99-104]. 
 After the AA has been released from phospholipids under stimulation conditions, 
it can be metabolized into eicosanoids through four different pathways, namely 
cyclooxygenase, lipoxygenase, cytochrome-P450 and oxygen species-triggered reactions 
(Figure 2). These pathways yield a plethora of compounds, such as prostaglandins, 
isoprostanes, thromboxane, leukotrienes, lipoxins and epoxyeicosatrienoic acids, all of 
which act in a paracrine/autocrine manner through specific receptors on the plasma 
membrane. 
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For the biosynthesis of prostaglandins and tromboxane from AA, synthesis of 
PGH2 via cyclooxygenase is the first step. Cyclooxygenase incorporates molecular O2 
and forms PGG2 that is subsequently reduced to form PGH2 by the action of the 
peroxidase active site. PGH2 is the substrate of different prostaglandin and thromboxane 
synthases that are expressed in tissues and cells in a selective-manner and lead to the 
formation of PGE2, PGD2, PGI2, PGF2α and TXA2 [105]. These compounds exert 
important biological functions, i.e. modulating smooth muscle tone, vascular 
permeability, hyperalgesia, fever and platelet aggregation [106].  
Leukotrienes, eoxins, lipoxins, and hydroperoxyeicosatetranoic acids (HPETEs) 
are synthesized from AA by lipoxygenase enzymes (5-, 12- and 15-lipoxygenase) that 
add molecular O2 into AA stereospecifically. 5-Lipoxygenase forms 5-
hydroperoxyeicosatetraenoic acid (5-HPETE) that is metabolized to LTA4 in a second 
step. LTA4 is unstable, and can rapidly be converted to LTB4, a potent chemoattractant 
for polymorphonuclear leukocytes. Additionally, LTA4 can be converted to LTC4 which 
is the precursor of LTD4 and LTE4. These three leukotrienes constitute the slow-reacting 
substances of anaphylaxis that act in the allergic response [107]. Eoxins are produced in a 
similar manner as the leukotriens, but by the action of 15-lipoxygenase, and are almost as 
potent as 5-lipoxygenase-derived leukotrienes [108]. Lipoxins are generated by 
transcellular biosynthesis and have anti-inflammatory and resolving roles [109]. 
Other metabolites, including epoxyeicosatrienoic acids (EETs) and their products 
from epoxy-ring hydrolysis, dihydroxyeicosatrienoic acids (DHETs), are derived from 
cytochrome-P450 enzymes [110]. EETs have been associated with anti-inflamatory 
properties in cardiovascular diseases [111].  
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The fourth pathway of production of eicosanoids is the reaction of AA with 
reactive oxygen species to yield a group of compounds known as isoprostanes. As 
radical-driven reactions are not stereo-selective, they generate different isomers with 
structures similar to those of prostaglandins. Because of their origin, isoprostanes have 
been used as markers of oxidative stress [112]. 
 
 
3. Lipidomic Studies of Cellular Arachidonate Metabolism 
 Traditionally, cellular studies on AA movement to and from glycerophospholipids 
made extensive use of radiolabeled fatty acid. After lipid extraction and chromatographic 
separation, quantification was carried out by scintillation counting [54-59, 66-76, 113-
119]. Studies carried out in the 80’s and early 90’s using this general strategy 
demonstrated that most of the AA incorporated into cellular phospholipids resides in PC, 
PE or PI, that the major AA-containing phospholipid classes in many cell types, —
especially those involved in innate immunity and inflammation reactions—, usually 
contain ether linkages at the sn-1 position, and that major remodeling reactions involving 
AA occur between PC (primarily diacyl) species and PE (primarily alkenyl) species [29, 
54-56,120-124]. However, a potential problem with the use of radioactive tracers is that 
sometimes, experiments are not carried out under equilibrium labeling conditions and, 
therefore, changes detected involve only discrete pools with higher turnover rates. 
Moreover, using this methodology, it is not possible to ascertain the exact molecular 
composition of the phospholipids to which AA is bonded. 
The advent of HPLC coupled to MS, or direct infusion MS, has made it routinely 
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possible to collect structure information, thus greatly strenghtening our knowledge on  
the cellular dynamics of AA. [12-14, 125-140]. Moreover, by using a metabolipidomic 
approach (i.e. combining the power of MS with use of stable isotopes such as deuterium-
labeled AA), dynamic information can also be obtained as to the differential mobilization 
of various cellular AA pools under defined stimulation conditions, thus allowing the 
understanding of lipid turnover in contrast with static measures under equilibrium 
conditions [15, 141].  
Identification of the phospholipid acyl chains as well as their positioning in the 
sn-1 versus the sn-2 position of the glycerol backbone can be obtained through 
fragmentation experiments (ESI-MS/MS). Such assignments are usually straightforward 
for analyses of AA-containing PE and PI in the negative ion mode. Analysis of AA-
containing PC species  is  usually carried out in negative mode with postcolumn addition 
of acetic acid, as [M+CH3CO2]- adducts [14, 127, 132, 136-138, 140]. 
 Using [2H]8AA and reverse phase-HPLC-ESI-MS, Balgoma et al. [142] identified 
the PI molecular species that initially incorporate AA in human U937 promonocyte-like 
cells and peripheral blood monocytes. The unusual species PI([2H]AA/[2H]AA) was 
found to behave as a major but short-lived acceptor of the AA, and its route of 
biosynthesis was described to involve the direct acylation of both the sn-1 and sn-2 
positions of PI. Likewise, similar studies on the initial incorporation of AA into PE 
species revealed a fundamental difference between human U937 promonocytes and 
peripheral blood monocytes in that the former, but not the later, incorporate large 
quantities into various PE molecular species at short times [61]. This difference is 
attributed to the higher remodeling rate of U937 cells compared to monocytes, which in 
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turn appears to be related to the intrinsically low AA content that these cells exhibit  [61]. 
 Rouzer et al. [143] compared the fatty acid remodeling of murine residential 
peritoneal macrophages and RAW 264.7 macrophage-like cells after exposure to yeast-
derived zymosan. Using tandem MS, AA deficiency of cultured cells compared with their 
primary counterparts was confirmed, as was the different distribution of AA among 
phospholipids in AA-enriched RAW 264.7 cells and peritoneal macrophages [143]. 
These data are relevant in that they emphasize the potential pitfalls of using AA-deficient 
cells by long term culture in studies of AA metabolism. Although this kind of studies 
have been useful to describe biochemical pathways, they have not always produced 
meaningful data from a physiological point of view, i.e. when compared with primary 
cells, since the AA deficiency of cultured cells usually results in much lower amounts of 
AA mobilized –and hence of eicosanoids produced–, and probably also the preferential 
use of AA phospholipid pools with higher turnover rates [74, 143].   
 In subsequent studies, Rouzer et al. [144] reported that the bulk of cPLA2α-
mediated AA release in zymosan-stimulated macrophages arises from AA-containing PC 
species whereas AA-containing PE species show little or no changes. Similar to these 
studies, using reverse phase HPLC-ESI-MS, Balgoma et al. [145] described that all major 
AA-containing PC and PI species decrease in a cPLA2α-dependent manner in zymosan-
stimulated human monocytes, with only minor changes in the levels of AA-containing PE 
species. Taking into account previous work utilizing [3H]AA-labeled cells under 
equilibrium labeling conditions [55-58], it seems likely that PE molecules also serve as 
immediate substrates for stimulus-induced AA mobilization in monocytes/macrophages, 
but these are rapidly reacylated using AA from other sources, e.g. PC, via CoA-IT-
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mediated reactions [144, 145]. In this regard, a previous lipidomic study with human 
platelets demonstrated that ethanolamine plasmalogen species constituted by far the 
major sources of AA mobilized after thrombin stimulation of the cells at very short times, 
i.e. 90 s [146]. Collectively, these studies highlight a key distinctive advantage of 
applying an ESI-MS lipidomics approach to the analysis of AA metabolism, that is, the 
possibility of identifying the specific molecular species of phospholipids that act as 
donors and acceptors of AA moieties during activation. Thus, conclusions can now be 
drawn on the molecular specificity of the phospholipid substrate and the phospholipid-
hydrolyzing phospholipase(s) involved. 
 In the above-mentioned studies with human monocytes [145], the levels of the 
two minor species PI(20:4/20:4) and PC(20:4/20:4) were found to increase in zymosan-
activated cells compared with resting cells, and a third species not present in resting cells, 
PE(16:1/20:4), appeared under stimulation conditions [145]. Analysis of the pathways 
involved in the synthesis of these three lipids indicated that PI(20:4/20:4) and 
PC(20:4/20:4) were produced in a deacylation/reacylation pathway via cPLA2α and acyl-
CoA synthetase–dependent reactions, whereas PE(16:1/20:4) was generated via a CoA-
independent transacylation reaction [145]. The finding that certain AA-containing species 
that are detected at low levels or not detected at all under resting conditions, significantly 
increase in activated cells via selected biosynthetic pathways suggests that they may be 
regarded as lipid markers of particular activation states of the cells.  
  Lipidomic profiling of AA-containing phospholipids may also be useful to define  
cell-specific differences. Figure 3 compares the distribution of AA-containing 
phospholipids in human peripheral blood monocytes [145], human monocyte-derived 
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macrophages [147], and mouse peritoneal macrophages [148], all obtained by reverse 
phase HPLC-ESI-MS under identical experimental conditions. Although the overall 
distribution of AA between glycerophospholipids is similar in the three cell types, some 
potentially useful differences  are  apparent. For example,  the  plasmalogen  species 
PC(P-16:0/20:4) is present at low levels in human monocytes and mouse macrophages 
but is by far the major AA-containing PC species of human macrophages. Similarly, 
PC(16:0/20:4) is present in trace amounts in human monocytes and macrophages but is 
one of the most abundant AA-containing PC species of mouse macrophages (Figure 3). 
As for human monocytes, note the conspicuous absence of the plasmalogen species 
PE(P-18:1/20:4) and PE(P-18:2/20:4), which is counteracted by the high level of the 
related species PE(P-18:0/20:4), compared to human and mouse macrophages. 
 Although not focusing directly on AA-containing phospholipids, other lipidomic 
studies looking for biomarkers in various macrophage cell types, have led to the 
identification of unusual glycerophospholipids such as ether-linked PI species, PE species 
containing very long fatty acyl chains, or phospholipids containing threonine as the polar 
headgroup [149]. Very recently, combining HPLC-ion trap MS and HPLC-triple 
quadrupole MS, Yang et al. [150] described changes in glycerophospholipid species in 
response to different levels of oxidative stress induced by H2O2 in EA.hy926 cells. In 
these studies, the authors identified 7 lysophospholipid correlating with cPLA2α 
activation under these conditions, which could potentially be regarded as biomarkers of 
oxidative stress conditions [150]. 
More ambitious lipidomic analyses have aimed at establishing the dynamics of 
lipid metabolism and regulation during inflammatory stimulation. Dennis et al. [151] 
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carried out the first quantitative approach for the characterization of the whole lipidome 
of an inflammatory cell.  Dynamic quantitative MS analyses were carried out, together 
with transcriptional measurements of genes involved in lipid metabolism in RAW 264.7 
macrophage-like cells stimulated with Kdo2-lipid A, or treated with the pharmacological 
inhibitor compactin. This work focused on 400 lipid species from all major lipid classes, 
including fatty acids, acyl-CoAs, eicosanoids, glycerophospholipids, sphingolipids, 
sterols and glycerolipids [151]. In cells stimulated with the specific TLR4 agonist Kdo2-
lipid A, a good correlation was observed between expression of genes coding for 
enzymes of lipid metabolism and changes of the corresponding metabolites. However a 
potential shortcoming is that this information could be misleading if the regulation of 
enzyme levels is post-transcriptional, as is the case of e.g. cPLA2α [151]. Increases in 
cholesterol, lanosterol and desmosterol were also documented, as well as increases in 
sphingolipid content, consistent with induction of the de novo biosynthesis of 
sphingolipids. Finally, significant changes in phosphatidic acid and PI species were 
detected, with increases of saturated and monounsaturated phosphatidic acid species, and 
decreases of polyunsaturated species such as PI(38:4) –probably PI(18:0/20:4)– at 24h, 
raising the possibility that lipid molecules involved in signaling still act beyond 24 h 
stimulation [151]. 
The application of MS techniques for eicosanoid quantitation has supposed a 
significant breakthrough in this field of research, since traditional analyses, based in 
enzyme-linked immunosorbent assays (ELISA) allow the analysis of only one eicosanoid 
per assay, thus prohibiting great-scale assays. By using a lipidomic approach, Norris et 
al. [152] analyzed the eicosanoid profile together with protein and gene expression of 
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enzymes of eicosanoid metabolism when different types of macrophages –murine 
residential peritoneal macrophages, bone marrow-derived macrophages, thioglycollate 
elicited macrophages and RAW 264.7 macrophage-like cells– were exposed to Kdo2-
lipid A. Over 140 species were detected, including AA-derived metabolites generated by 
COX, LOX and CYP450 pathways (Figure 2) and those derived from non-enzymatic 
pathways. Lower levels of ω-3 fatty acid-derived protectins and resolvins were also 
detected. In addition, adrenic acid-derived dihomoprostaglandins [23-25] were detected 
in all macrophage types, suggesting that these compounds may possess biological 
significance. Overall, the data confirmed that although there are potentially many factors 
that affect eicosanoid production such PLA2 activation, the enzymes of the AA 
reacylation pathway (Figure 1), and terminal synthases, the delayed phase of 
prostaglandin production by all macrophage types was strikingly dependent on the 
maximal level of COX-2 expression [152].  
 Andreyev et al. [153] focused their lipidomic analyses on the different subcellular 
localization of lipid species in RAW 264.7 cells, analyzing a total of 229 species in  
various compartments such as endoplasmic reticulum, mitochondria, nuclei, 
plasmalemma and cytoplasm, and addressing the changes occurring upon activation with 
Kdo2-lipid A. Cell activation led to remodeling of the lipidome in all subcellular 
compartments, apparently in an organelle-specific manner. Changes detected included 
increases in phosphatidic acid in the endoplasmic reticulum –suggestive of phospholipase 
D activation in that compartment– or increases in highly unsaturated cardiolipins and  
oxidized sterols in mitochondria –suggestive of oxidative stress in this organelle–. In 
addition, ether-linked phospholipids increased in plasma membrane but decreased in the 
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endoplasmic reticulum under stimulation conditions, especially the ether species PE(P-
38:4/O-38:5), which probably contains AA [153]. 
 
 
4. Concluding Remarks and Future Perspectives 
The robustness and sensitivity of mass spectrometry converts this technique in the 
preferred tool for lipidomic analyses, which focuses on the complete characterization of 
lipid species in combination with gene/protein expression under different conditions or 
aiming at the understanding of turnover and lipid pathways. In this regard, lipidomic 
approaches, specifically the use of ESI-MS/MS with or without a previous HPLC 
separation and alternative use of deuterated compounds, permit the thorough 
characterization of cellular AA dynamics with regard to incorporation into and 
remodeling between different phospholipid classes, and the liberation of the fatty acid 
and oygenation to form eicosanoids. Current analysis and characterization of these 
processes in the context of lipidomics has helped to understand new regulatory features 
of AA pathways of physiological and pathophysiological relevance. The study of AA 
regulation along with data from proteomics and genomics will enable the in-depth 
knowledge of the role of AA in different cell types and patients. This holistic point of 
view will put AA trafficking and metabolism in the context of systems biology 
approaches [154]. 
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Figure Legends 
 
Figure 1. AA incorporation in glycerophospholipids. AA is obtained directly from diet or 
synthesized from linoleic acid. Afterward, AA is incorporated into the sn-2 position of  
glycerophospholipids and later subjected to remodeling processes via CoA-IT-dependent 
reactions. ACS: acyl:CoA synthetase; LPCAT: lysophosphatidylcholine:acyl-CoA 
acyltransferase; PLA2: phospholipase A2; CoA-IT: independent-CoA transacylase. 
 
Figure 2. The four pathways for AA metabolism into eicosanoids four different 
pathways; cyclooxygenase, lipoxygenase, cytochrome-P450 and non-enzymatic oxidation 
reactions. 
 
Figure 3. AA-containing PC, PE and PI species in human monocytes (blue), human 
monocyte-derived macrophages (red) and mouse peritoneal macrophages (green). Data  
represent means of three independent determinations (S.E.M. < 15% for all 
determinations), and are given as a percent with respect to the total amount of AA-
containing phospholipids. For further details see text. Shorthand notation of 
glycerophospholipids (abscissa) follows the guidelines proposed by Fahy et al. [155]. 
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